GEN Exclusives

More »

GEN News Highlights

More »
Jun 21, 2007

Schizophrenia and Bipolar Mania Treatment in Adolescents and Children Added to Risperdal’s Label

  • Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) received an approvable letter regarding two sNDAs for Risperdal®. The sNDAs are for the treatment of schizophrenia in adolescents between 13-17 years and for the short-term treatment of bipolar mania associated with bipolar I disorder in children and adolescents between 10-17 years.

    The FDA has not asked for any additional studies, according to J&JPRD. The company says that it is currently reviewing the letter and then will finalize the label with FDA.

    Risperdal is already approved for the treatment of bipolar I disorder and acute to manic or mixed episodes associated with bipolar mania.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?